Carboxypeptidase

2-PMPA (2-(Phosphonomethyl)pentanedioic acid) 是谷氨酸羧肽酶II 的选择性抑制剂(IC50:300 pM)。

2-MPPA (GPI-5693) 是一种具有口服活性、选择性和高效性的谷氨酸羧肽酶 II (GCP II) 抑制剂（IC50：90 nM），也是 NAALADase 抑制剂，可用于研究神经系统疾病。

CPA inhibitor (Carboxypeptidase inhibitor) 是一种有效的羧肽酶 A (CPA) 抑制剂，Ki 值为 0.32 μM。

BAY-299是一种有效的抑制剂，能抑制 bromodomain 和 PHD 指家族成员 BRPF2以及 TATA 盒结合蛋白相关因子 TAF1和 TAF1L，其IC50分别为67 nM、8 nM 和106 nM。

GNE-375 是一种具有选择性和高效性的 BRD9 抑制剂，(IC50：5 nM)。GNE-375 抑制 BRD4、TAF1 和 CECR2，可用于研究表观遗传学耐药性。

CeMMEC1 是一种 BRD4 抑制剂，对 TAF1 有很好的亲和力，IC50为0.9 μM。

Carboxypeptidase G2 (CPG2) Inhibitor (CPG2 Inhibitor) 是新型的羧肽酶 G2(CPG2)抑制剂，显示出抗癌活性。

CeMMEC13 是一种异喹啉酮，可选择性抑制 TAF1 的第二个溴结构域，IC50为 2.1 μM。

2-Benzylsuccinic acid (DL-Benzylsuccinic acid) 是羧肽酶 A (CPA) 抑制剂。

Benzoylphenylalanine (LBPA) 可用作光亲和肽灭活剂。

Spinorphin 是一种脑非肽降解酶抑制剂，能够抑制氨基肽酶、二肽基氨基肽酶III、血管紧张素转换酶和脑非肽酶。它可用于研究疼痛的缓解。

GCPII-IN-1 TFA (compound 2)是一种谷氨酸羧肽酶 II(GCPII,glutamate carboxypeptidase II，PSMA)的抑制剂支架，Ki=44.3±2.4 nM，能够与生物素结合蛋白或纳米颗粒连接并靶向表达GCPII的细胞，可用于前列腺癌。

Sortin1, a chemical genetic-hit compound, specifically induces mislocalization of both soluble and membrane-associated vacuolar markers in plants and yeast.This compound is unstable in powder form and other related salt forms are recommended.

AZD-9684, a carboxypeptidase U inhibitor, is used potentially for the prevention of thrombosis.

GEMSA 是一种有效的脑啡肽转化酶抑制剂 (enkephalin convertase,Ki=8.8 nM)，具有镇痛作用。

Mergetpa作为一种羧肽酶抑制剂，其功能是阻碍激肽及B2受体拮抗剂转变成无c末端精氨酸的代谢物。

Belactin A 是一种抑制剂，可作用于vasohibin-1（VASH-1），其半数抑制浓度（IC50）为0.18 µg/ml。

Histargin is an enzyme inhibitor separated from Streptomyces roseoviridis.

PMPA sodium is a potent and selective glutamate carboxypeptidase 2 (GCP II/N-acetylated a-linked dipeptidase/NAALADase) inhibitor.

Monosodium 2-sulfoterephthalate (8) 是glutamatecarboxypeptidaseII的抑制剂。

CarboxypeptidaseC为生化研究中常用的羧肽酶，专门用于切除多肽链羧基末端的赖氨酸、精氨酸和脯氨酸，同时也能处理包含中性、脂肪族、芳香族及酸性蛋白质氨基酸的肽链。

D-DOPA is an enantiomer of the dopamine precursor L-DOPA . It can be converted to L-DOPAviasequential oxidation and transamination, which are mediated by D-amino acid oxidase (DAAO) and DOPA transaminase, respectively, in rat kidney homogenates.1It reduces the number of dopaminergic neurons in primary rat embryonic mesencephalic cultures in a concentration-dependent manner.2Intraventricular administration of D-DOPA (200 μg/animal) increases striatal dopamine levels in rats.3D-DOPA (20 mg/kg, i.p.) induces contralateral turns in a rat model of Parkinson's disease induced by 6-OHDA .4 1.Wu, M., Zhou, X.-J., Konno, R., et al.D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminaseClin. Exp. Pharmacol. Physiol.33(11)1042-1046(2006) 2.Ling, Z.-D., Pieri, S.C., and Carvey, P.M.Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neuronsClin. Neuropharmacol.19(4)360-365(1996) 3.Karoum, F., Freed, W.J., Chuang, L.-W., et al.D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in ratsBrain Res.440(1)190-194(1988) 4.Moses, J., Siddiqui, A., and Silverman, P.B.Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian ratNeurosci. Lett.218(3)145-148(1996)

GCPII-IN-1 is a potent inhibitor scaffold targeting glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA). It exhibits a high affinity for GCPII, with a binding affinity (K i ) of 44.3 nanomolar (nM).